|
|
 ADDENDUM - KIEGÉSZÍTÉS .. JOSEPH G. SINKOVICS: THE "MELANOMA-SARCOMA SERVICE" IS STILL REPORTING CÍMŰ KÉZIRATÁHOZ |
| The late-break multi-authored (10 authors), multi-institutional (21 centers) abstract #CRA#9011 entitled “A phase III multiinstitutional randomized study of immunization with the gp100-209-217(210M) peptide followed by high-dose IL-2 (720,000 international unit/kg/dose) compared with high-dose IL-2 alone in patients with metastatic melanoma” was presented by D. J. Schwartzentruber on June 2, 2009 on the last day of the 45th ASCO conference in Orlando, FL. This prospectively randomized clinical trial was conducted to re-test the preliminary positive results of a prior non-randomized study involving 31 patients (S. A. Rosenberg et al Nature Medicine 4:321-327 1998). Eligible patients had stage IV (without brain metastases), or locally advanced stage III disease, and were positive for HLA A0201. In evaluable 93 control patients (IL-2 alone) and in evaluable 86 immunized (peptide vaccine and IL-2) patients the documented responses were 9.7% versus 22.1% (P=0.0223). Median overall survivals were 12.8 months versus 17.6 months (P=0.0964). This prospectively randomized clinical trail is considered to be a valid proof for the efficacy of a melanoma vaccine. |
|
|
| Magyar Epidemiológia |  |
| Bejelentkezés | |
|
|
